Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 20% IN WATER vs MANNITOL 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, which inhibits water reabsorption and promotes diuresis.
Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.
Reduction of intracranial pressure and cerebral edema,Reduction of elevated intraocular pressure,Promotion of diuresis in acute renal failure (as an adjunct),Treatment of dialysis disequilibrium syndrome,Management of oliguric phase of acute renal failure
Reduction of elevated intracranial pressure,Promotion of diuresis in acute renal failure,Reduction of intraocular pressure,Adjunct in treatment of acute oliguric renal failure,Management of cerebral edema
1-2 g/kg (5-10 m L/kg of 20% solution) intravenously over 30-60 minutes for reduction of intracranial pressure; may repeat every 6-8 hours. For preoperative bowel preparation, 100-200 m L (20% solution) orally.
Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.
0.25–1.5 hours (15–90 minutes) in patients with normal renal function. In oliguric or anuric patients, half-life is markedly prolonged, up to 36 hours, due to reduced clearance.
Terminal elimination half-life is 0.25–1.5 hours; prolonged in renal impairment (up to 36 hours).
Not metabolized; excreted unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Mannitol is not metabolized; it is excreted unchanged by the kidneys via glomerular filtration.
Primarily renal excretion as unchanged drug. Over 90% of administered dose is excreted unchanged in urine within 24 hours. Less than 5% is metabolized in the liver; negligible biliary/fecal elimination.
Renal: >90% as unchanged drug; minimal biliary or fecal excretion.
Negligible (<5%); essentially unbound.
Negligible (<0.1%); no specific binding proteins.
Approximately 0.3–0.6 L/kg. Mannitol distributes primarily in extracellular fluid; does not cross cell membranes readily unless administered in large doses or under pathological conditions (e.g., disrupted blood-brain barrier). Increased Vd may indicate expanded extracellular volume.
0.2–0.5 L/kg; primarily confined to extracellular fluid; increases with dehydration.
Intravenous: 100%. Oral: Not applicable; not administered orally due to poor absorption and osmotic diarrhea. Other routes (e.g., subcutaneous or intramuscular) are not clinically relevant.
IV: 100%; oral: <10% due to poor absorption.
Contraindicated in anuria or severe renal impairment (Cr Cl < 30 m L/min). Use with caution if Cr Cl < 50 m L/min; monitor serum osmolality and urine output. No specific dose adjustment guidelines exist; consider alternative therapy.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolarity and urine output. No specific dose for GFR >50 m L/min.
No specific adjustment required for hepatic impairment. Use with caution in severe liver disease due to risk of fluid overload.
No specific dose adjustment for hepatic impairment. Caution in patients with cirrhosis due to risk of fluid overload.
For reduction of intracranial pressure: 0.25-1 g/kg (1.25-5 m L/kg of 20% solution) intravenously over 30-60 minutes, repeated every 6-8 hours as needed. Maximum dose: 2 g/kg/day.
Children: For reduction of intracranial pressure, 0.25-1 g/kg as a 15-25% solution IV over 30-60 minutes. For diuresis, 0.5-2 g/kg as a 5-25% solution IV every 6-12 hours. Maximum dose 2 g/kg/dose.
Start at lower end of dosing range (0.5 g/kg) due to increased risk of renal impairment and hypovolemia. Monitor serum electrolytes, osmolality, and renal function closely. Avoid in patients with significant cardiovascular disease.
Elderly: Use lower doses and titrate carefully due to increased risk of fluid overload, electrolyte disturbances, and renal impairment. Monitor renal function and serum osmolarity. Start with the lower end of adult dosing range.
No FDA boxed warning.
None
Risk of pulmonary edema or congestive heart failure due to volume expansion,May cause electrolyte imbalance (e.g., hyponatremia, hyperkalemia) and dehydration,Monitor renal function; contraindicated in anuria or severe renal impairment,May increase intracranial pressure rebound effect,Use with caution in patients with severe hypovolemia or electrolyte disorders,Intravenous administration requires careful monitoring of fluid and electrolyte status
May cause volume expansion and pulmonary edema in patients with impaired renal function. Monitor renal function, serum electrolytes, and fluid balance. Avoid extravasation as it may cause tissue necrosis. Use with caution in patients with congestive heart failure or severe dehydration.
Anuria due to severe renal disease,Severe pulmonary congestion or pulmonary edema,Severe dehydration,Intracranial hemorrhage (unless during craniotomy) or active intracranial bleeding,Hypersensitivity to mannitol or any component of the formulation
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, known hypersensitivity to mannitol.
No significant food interactions. However, patients on this therapy often have restricted fluid and electrolyte intake; follow prescribed dietary restrictions, especially regarding sodium and fluid intake, as directed by the healthcare team.
No significant food interactions; maintain adequate hydration unless contraindicated.
Osmitrol 20% is a hyperosmolar agent used for osmotic diuresis. Based on animal studies and human data, mannitol crosses the placenta. In the first trimester, there is a theoretical risk of fetal osmotic shifts, but no well-controlled studies exist. In the second and third trimesters, use may cause fetal dehydration and electrolyte disturbances. Due to its limited indications in pregnancy (e.g., for elevated intracranial pressure), the risk-benefit must be carefully evaluated. Mannitol is assigned to FDA Pregnancy Category C.
Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First trimester: theoretical risk from osmotic shifts. Second/third trimester: monitor for maternal hemodynamic changes (e.g., pulmonary edema) that may affect placental perfusion.
It is unknown if mannitol is excreted in human milk. Given its high molecular weight and low lipid solubility, excretion is likely minimal but not confirmed. Caution is advised; use only if clearly needed. M/P ratio is not available.
Unknown if excreted in human milk. No available data on M/P ratio. Consider benefits of breastfeeding vs. potential risk of osmotic effects or maternal dehydration. Caution advised.
Pharmacokinetic changes in pregnancy (increased plasma volume, increased renal clearance) may require dose adjustments. However, mannitol dosing is titrated to effect (e.g., urine output, serum osmolality). Pregnancy may reduce the duration of action. Monitor clinical response more frequently and adjust dose as needed to maintain desired osmolality and avoid toxicity.
No specific dose adjustments recommended for pregnancy alone. Consider increased plasma volume in pregnancy; monitor for volume overload. Dose based on clinical response and renal function. Avoid rapid infusion.
Monitor serum osmolarity and sodium levels closely; risk of hypematremia and hyperosmolality, especially in renal impairment. Use with caution in patients with congestive heart failure or pulmonary congestion. Administer via central line to avoid phlebitis. In acute renal failure, a test dose of 0.2 g/kg over 3-5 minutes may be given; if urine flow increases > 40 m L/h, full therapy can be initiated. Taper abruptly to avoid rebound intracranial hypertension. Contraindicated in anuria, intracranial hemorrhage, severe dehydration, and glucose intolerance (use with caution in diabetics).
Administer via large-bore IV; monitor serum osmolality and renal function; ensure urine output >30 m L/h; avoid extravasation; use with caution in patients with pulmonary congestion or CHF.
This medication may cause you to urinate frequently; it is used to reduce brain swelling or to promote urine output.,You may experience headache, nausea, blurred vision, or thirst; report these to your healthcare provider.,Your fluid intake and output, as well as blood tests (electrolytes, kidney function), will be monitored closely.,Do not stop taking this medication abruptly without consulting your doctor; sudden withdrawal may worsen your condition.,Inform your doctor if you have heart disease, kidney disease, or diabetes.,This medication is given intravenously, usually in a hospital setting.
You may experience increased urination during treatment.,Report any chest pain, difficulty breathing, or swelling to your doctor immediately.,You may feel thirsty or have a dry mouth; this is expected.,Your blood sugar levels may be monitored if you have diabetes.,Avoid consuming large amounts of salt or salty foods.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 20% IN WATER vs MANNITOL 10% IN PLASTIC CONTAINER, answered by our medical review team.
OSMITROL 20% IN WATER is a Osmotic Diuretic that works by Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, which inhibits water reabsorption and promotes diuresis.. MANNITOL 10% IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolarity, drawing water from tissues into the bloodstream and enhancing water excretion by the kidneys. It also reduces intracranial pressure by creating an osmotic gradient across the blood-brain barrier.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 20% IN WATER and MANNITOL 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 20% IN WATER is: 1-2 g/kg (5-10 m L/kg of 20% solution) intravenously over 30-60 minutes for reduction of intracranial pressure; may repeat every 6-8 hours. For preoperative bowel preparation, 100-200 m L (20% solution) orally.. The standard adult dose of MANNITOL 10% IN PLASTIC CONTAINER is: Adults: 50-100 g intravenously over 30-60 minutes, typically as a 15-25% solution. For reduction of intracranial pressure, 1.5-2 g/kg as a 20% solution IV over 30-60 minutes. For promotion of diuresis, 50-100 g as a 5-25% solution IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 20% IN WATER and MANNITOL 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 20% IN WATER is classified as Category C. Osmitrol 20% is a hyperosmolar agent used for osmotic diuresis. Based on animal studies and human data, mannitol crosses the placenta. In the first trimester, there is a theoretica. MANNITOL 10% IN PLASTIC CONTAINER is classified as Category A/B. Mannitol 10% is a hyperosmolar agent. Limited human data. No known teratogenic effects reported in animal studies. Fetal risk cannot be excluded; use only if clearly needed. First . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.